Correlating whole blood AR-V7 and AR-V9 with therapy response to AR-targeted therapies in metastatic castrate-resistant prostate cancer (mCRPC).

Edmond Michael Kwan,Sarah Q. To,Heidi Fettke,Andrew Mant,Maria Docanto,Patricia Bukczynska,Nicole Ng,Lisa Jane Graham,Phillip Parente,Carmel Pezaro,Kate Lynette Mahon,Lisa G. Horvath,Tilman Todenhöfer,Arun Azad

Correlating whole blood AR-V7 and AR-V9 with therapy response to AR-targeted therapies in metastatic castrate-resistant prostate cancer (mCRPC).

2018

Edmond Michael Kwan
Sarah Q. To
Heidi Fettke
Andrew Mant
Maria Docanto
Patricia Bukczynska
Nicole Ng
Lisa Jane Graham
Phillip Parente
Carmel Pezaro
Kate Lynette Mahon
Lisa G. Horvath
Tilman Todenhöfer
Arun Azad

e17070Background: The expression of androgen receptor splice variants (AR-V) in mCRPC patients has widely been regarded as a predictive biomarker for non-response to AR-targeted therapies. However,...

Keywords:

Whole blood
Castrate-resistant prostate cancer
Oncology
Pathology
Medicine
Internal medicine
predictive biomarker
therapy response
Androgen receptor

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations